CD5L:p40 Heterodimers Modulate Immune Response via IL-23 Receptor
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases and inflammatory-related cancers lack effective methods to modulate immune responses, particularly in regulating T cell function and IL-23 receptor expression, leading to inadequate control of hyperimmune responses and tumor progression.
Innovation Solution
Administration of recombinant soluble CD5L, CD5L homodimers, or CD5L:p40 heterodimers to modulate immune responses by inhibiting their binding to the IL-23 receptor, using nucleic acids or antibodies to target CD5L and p40, and employing immunotherapies like checkpoint inhibitors and adoptive T cell therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for autoimmune diseases and inflammatory-related cancers are used, then disease management is maintained, but effective modulation of immune responses and regulation of T cell function is insufficient
Solution Approach 1:
The patent uses CD5L and its heterodimer with p40 as intermediary molecules that bind to the IL-23 receptor, thereby mediating the modulation of immune responses. These intermediaries interfere with the binding of IL-23 to its receptor, suppressing pathogenic T cell responses while maintaining regulatory T cell function, thus resolving the contradiction between reliable control and adaptable modulation of immune responses.
2Reliability
If IL-23 pathway is activated to enhance anti-tumor immunity, then tumor progression is controlled, but excessive immune responses and inflammation are exacerbated
Solution Approach 1:
The patent applies local quality by differentiating the effects of CD5L modulation on different T cell subsets. By specifically suppressing pathogenic T cell responses (reducing harmful factors) while preserving or enhancing regulatory T cell function (maintaining beneficial anti-tumor immunity), the treatment achieves localized modulation of immune quality rather than blanket suppression or activation.
3Reliability
If CD5L homodimers are used to modulate immune response, then binding to IL-23 receptor is inhibited, but formation of functional heterodimers with p40 is reduced
Solution Approach 1:
The patent employs CD5L homodimers as a functional copy or alternative form that can substitute for the heterodimeric CD5L:p40 complex in mediating immune modulation. The homodimers replicate the essential function of binding to and inhibiting the IL-23 receptor pathway, providing a simplified version that achieves the same therapeutic effect without requiring p40 partner formation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach effectively suppresses excessive immune responses in autoimmune diseases and enhances anti-tumor immunity by regulating T cell function and IL-23 receptor expression, thereby reducing disease severity and tumor growth.
Implementation Method 1
CD5L and p40 form heterodimers in vivo, and that these heterodimers modulate the immune response
Implementation Method 2
Some embodiments comprise methods for modulating an immune response or suppressing an immune response (e.g., an inflammatory immune response) in a subject, the method comprising administering to the subject a therapeutically effective amount of recombinant soluble CD5L, a CD5L:CD5L homodimer, a CD5L:p40 heterodimer
Implementation Method 3
In some embodiments, the agent comprises an antibody, or an antigen binding fragment thereof, that binds to one or more of the CD5L, the CD5L homodimer, or the CD5L:p40 heterodimer
Data Source
Figure 1
Figure 2
Figure 3A
AI summary
Described herein are methods for suppressing an immune response in a subject, e.g., a subject with an autoimmune disease, by administering to the subject a therapeutically effective amount of recombinant CD5L, CD5L homodimers and/or CD5L:p40 heterodimers, or nucleic acids encoding any of these. Also described are methods for enhancing an immune response in a subject, e.g., a subject with cancer, infection, or an immune deficiency, by administering to the subject a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds specifically to CD5L, D5L homodimers and/or CD5L:p40 heterodimers, and inhibits their binding to the IL-23 receptor, or inhibits formation of the CD5L homodimer and/or CD5L:p40 heterodimer, or inhibitory nucleic acids that target CD5L and/or p40.